Alembic Ltd

Stage 2 · Advancing · week 10Setup 8.0 ★★★ PrimeEven −0.1

As of 20 Nov 2026, Alembic is in Stage 2, the uptrend phase, now in week 10 (since 8 Sep 2026). It closed at ₹109, 5.8% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Alembic Limited engages in real estate business in India and internationally. More about the company

₹108.9
Close, 20 Nov 2026
-2.31% on the day
₹2,797 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

In a healthy advance

Setup score

8.0 ★★★ Prime

RS rank

Edge

Even −0.1

ALEMBICLTD is about 2 months into its Stage 2 advance, 7% above its 50-day average and 6% under its 52-week high. With the trend established, this middle stretch has tended to be the steadiest part of a move.

Its relative strength is 72 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Stocks with a similar setup at this point in their move ran 0.1 points behind the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 15% above entry.

The trend read holds while it stays in Stage 2. A close below ₹101, its 50-day average, would put it at rest; ₹92.54, 20% under its 52-week high of ₹116, is where a trailing stop would sit.

Setup-score rank among Stage 2 peers: #23 of 50 in Pharmaceuticals · #30 of 61 in Health Care

Is ALEMBICLTD early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 30w
S2 19w
S4 14w
S4 41w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 30w → S3 11w → S2 19w → S3 11w → S2 3w → S3 3w → S4 14w → S1 11w → S2 2w → S4 41w → S1 7w → S4 4w → S1 2w → S2 11w current
Total tracked: 169 weeks across 14 stage runs.

ALEMBICLTD among Pharmaceuticals59th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…59ALEMBICLTDStage 2 · wk 1072+18.4%
vs 52W High
-5.8%
₹70.9 lo₹115.7 hi
5.8% below 52W high, pullback range
How far this stock is from its 52-week high. A stock a little below its high with its Stage 2 structure intact is in a pullback, not a breakdown.
Stage Maturity
Week 10
1w13w26w
Week 10, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
17.5%
200 DMA: ₹92.7 · rising
The stock is above its 200-day average, the long-term trend line. That is where a Stage 2 advance normally trades.
Rel Volume
0.37x
vs 50-day avg
Volume was well below average. In a Stage 2 advance, quiet sessions read as the stock resting, not being sold.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+18.4%
3M
+23.2%
6M
+24.8%
YTD
+7.6%
1Y
+7.9%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
This stock ranks #47 of 58 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Ranks #39 of 48 Stage 2 stocks in this industry.

Mutual fund holdings

Held by 3 mutual funds in portfolios to October 2026: 0 active funds and 3 index funds and ETFs.

In October, no active fund changed its holding.

All 3 funds and what each did in October

Mutual funds holding ALEMBICLTD: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 12 Oct 2026
Last appeared 8 Sep 2026
15 appearances in the last 60 days.
Recent Stage Timeline
2026-11-20S2
Wk 10 · Vol 0.37x
2026-11-19S2
Wk 10 · Vol 0.27x
2026-11-18S2
Wk 10 · Vol 0.23x
2026-11-17S2
Wk 10 · Vol 0.36x
2026-11-16S2
Wk 10 · Vol 0.59x
2026-11-13S2
Wk 9 · Vol 1.21x
2026-11-12S2
Wk 9 · Vol 1.04x
2026-11-11S2
Wk 9 · Vol 4.11x
2026-11-09S2
Wk 9 · Vol 19.37x
2026-11-06S2
Wk 9 · Vol 1.31x
2026-11-05S2
Wk 8 · Vol 0.56x
2026-11-04S2
Wk 8 · Vol 1.43x
Moving averages & range
50 DMA
₹101.5
200 DMA
₹92.7
52W High
₹115.7
52W Low
₹70.9
5D Low
₹108.9
Resistance levels (recent highs)
20d High
₹115.7
60d High
₹115.7
120d High
₹115.7
250d High
₹115.7
Next resistance
+6.2%
to 20d High
P/E (TTM)
9.1
Forward 2.3
Earnings Growth (YoY)
+5.4%
Revenue -2.0%
ROE
+13.3%
Profit margin +134.2%
Dividend Yield
2.12%
P/B 1.2

Alembic: quick answers

What stage is Alembic in?

As of 20 Nov 2026, Alembic (ALEMBICLTD) is in Stage 2, the uptrend phase. It entered Stage 2 on 8 Sep 2026 and is in week 10. What the four stages mean

Is Alembic in an uptrend?

Yes. Alembic is in a Stage 2 uptrend. It trades 17.5% above its 200-day average, which is rising.

How far is Alembic from its 52-week high?

Alembic closed at ₹109 on 20 Nov 2026, 5.8% below its 52-week high of ₹116. Its 52-week low is ₹70.90.

How has Alembic performed over the past year?

As of 20 Nov 2026, Alembic is up 7.9% over the past year and up 7.6% so far in 2026.

Which sector and industry is Alembic in?

Alembic is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Alembic Limited engages in real estate business in India and internationally. It operates through Active Pharmaceutical Ingredient (API) and Real Estate segments. The company constructs residential and commercial real estate projects; provides project management and marketing consultancy services; and leases commercial properties. It also manufactures and markets fermentation and chemistry based active pharmaceutical ingredient; and engages in research and development activities. In addition, it is involved in power generation through co-generation plants and wind power sources. The company serves individuals, entrepreneurs, corporates, business houses, HNIs, NRIs, and pharmaceutical companies. The company was incorporated in 1907 and is based in Vadodara, India. Alembic Limited is a subsidiary of Nirayu Pvt. Ltd.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.